Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer

In this study, we conducted an indirect comparison analysis to compare the efficacy and safety of immune checkpoint inhibitors with those of antiangiogenic therapy—two effective treatment methods for advanced non–small-cell lung cancer (NSCLC). Eligible randomised control trials of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jin-Hua, Yang, Jia-Lian, Chou, Che-Yi, Wang, Jiun-Yi, Hung, Chin-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018789/
https://www.ncbi.nlm.nih.gov/pubmed/29946182
http://dx.doi.org/10.1038/s41598-018-27994-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018789/
https://www.ncbi.nlm.nih.gov/pubmed/29946182
http://dx.doi.org/10.1038/s41598-018-27994-x

Ejemplares similares